Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2010 1
2011 3
2012 1
2013 2
2015 1
2016 1
2017 4
2018 5
2019 7
2020 4
2021 5
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of the Implementation of Multiple Enhanced Recovery After Surgery Pathways Across a Provincial Health Care System in Alberta, Canada.
Nelson G, Wang X, Nelson A, Faris P, Lagendyk L, Wasylak T, Bathe OF, Bigam D, Bruce E, Buie WD, Chong M, Fairey A, Hyndman ME, MacLean A, McCall M, Pin S, Wang H, Gramlich L. Nelson G, et al. Among authors: hyndman me. JAMA Netw Open. 2021 Aug 2;4(8):e2119769. doi: 10.1001/jamanetworkopen.2021.19769. JAMA Netw Open. 2021. PMID: 34357394 Free PMC article.
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: hyndman me. Urol Oncol. 2022 Jan;40(1):9.e1-9.e7. doi: 10.1016/j.urolonc.2021.03.024. Epub 2021 Jun 4. Urol Oncol. 2022. PMID: 34092482
Tissue-selective alternate promoters guide NLRP6 expression.
Bracey NA, Platnich JM, Lau A, Chung H, Hyndman ME, MacDonald JA, Chun J, Beck PL, Girardin SE, Gordon PM, Muruve DA. Bracey NA, et al. Among authors: hyndman me. Life Sci Alliance. 2020 Dec 29;4(3):e202000897. doi: 10.26508/lsa.202000897. Print 2021 Mar. Life Sci Alliance. 2020. PMID: 33376129 Free PMC article.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: hyndman me. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.
Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y. Grivas P, et al. Among authors: hyndman me. Urol Oncol. 2020 Apr;38(4):262-268. doi: 10.1016/j.urolonc.2019.11.004. Epub 2019 Dec 4. Urol Oncol. 2020. PMID: 31812633
30 results